The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate - Scorecard - MDSpire

The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate

  • By

  • R Humeniuk

  • M Rosu-Myles

  • J Fares

  • R Koller

  • J Bies

  • L Wolff

  • January 4, 2013

  • 0 min

Share

Clinical Scorecard: The function of tumor suppressor p15Ink4b in influencing the fate of hematopoietic progenitor cells

At a Glance

CategoryDetail
ConditionMyelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Key MechanismsSilencing of CDKN2B (p15INK4b) gene leads to skewed hematopoietic progenitor differentiation favoring granulocyte–macrophage progenitors over megakaryocyte–erythroid progenitors without affecting proliferation or apoptosis
Target PopulationPatients with MDS and leukemia exhibiting silenced p15INK4b expression
Care SettingHematology and oncology clinical and research settings

Key Highlights

  • 60–80% of human leukemia and MDS cases show silenced p15INK4b expression, associated with leukemic transformation and poor prognosis.
  • Loss of p15Ink4b skews blood cell formation towards granulocyte–macrophage progenitors at the expense of erythroid lineage commitment.
  • p15Ink4b expression serves as a prognostic marker for response to DNA methylation inhibitor treatment.

Guideline-Based Recommendations

Diagnosis

  • Assess p15INK4b gene expression status in patients diagnosed with MDS or leukemia to evaluate prognosis.

Management

  • Consider DNA methylation inhibitors in patients with silenced p15INK4b expression as p15INK4b may predict treatment response.

Monitoring & Follow-up

  • Use p15INK4b expression levels as a biomarker to monitor therapeutic response and disease progression.

Risks

  • Silencing of p15INK4b is linked to increased risk of leukemic transformation and poor clinical outcomes.

Patient & Prescribing Data

Patients with MDS and leukemia exhibiting p15INK4b silencing

p15INK4b expression status may guide the use of DNA methylation inhibitors and predict treatment efficacy.

Clinical Best Practices

  • Evaluate hematopoietic progenitor cell lineage commitment patterns in research or clinical investigations of MDS and leukemia.
  • Incorporate p15INK4b gene expression analysis in diagnostic and prognostic workflows for hematological malignancies.
  • Utilize inducible expression systems in research to study p15Ink4b function and its role in erythroid lineage commitment.

References

Original Source(s)

Related Content